Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides

被引:11
作者
Belliard, G
Hurtrel, B
Moreau, E
Lafont, BAP
Monceaux, V
Roques, B
Desgranges, C
Aubertin, AM
Le Grand, R
Muller, S
机构
[1] CNRS, UPR 9021, Inst Biol Mol & Cellulaire, F-67000 Strasbourg, France
[2] Inst Pasteur, Unite Physiopathol Infect Lentivirales, Paris, France
[3] INSERM, EMI 03 34, Inst Genet Mol, Paris, France
[4] INSERM, ULP U544, Inst Virol, Strasbourg, France
[5] INSERM, U266, Fac Pharm, CNRS FRE 2463, Paris, France
[6] CEA, Serv Neurovirol, Fontenay Aux Roses, France
关键词
HIV tat; antibodies; Rhesus macaques;
D O I
10.1016/j.vaccine.2004.08.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The human immunodeficiency virus (HIV) regulatory protein Tat represents an attractive target for developing vaccine strategies. Both Immoral and cellular responses against Tat might reduce disease progression by interfering with the deleterious functions of extracellularly secreted protein and by reducing viral replication. We have immunized Rhesus macaques intramuscularly and intranasally with a cocktail of three Tat peptides encompassing residues 1-20, 1-61 and 44-61 administrated in the presence of Montanide ISA 720 as adjuvant. The monkeys were challenged by the intrarectal route with 10 MID50 of SHIV BX08. All immunized macaques but one gave a good cross-reactive antibody response to Tat but the proliferative response and levels of IL-2, 1FN-gamma and TNF-alpha secretion of peripheral blood mononuclear cells (PBMCs) recalled ex vivo with active Tat protein were weak. After viral challenge one peptide-vaccinated macaque only remained free of virus. The presence in the serum of vaccinated animals of neutralizing antibodies able to inhibit Tat transactivation activity or Tat-induced apoptosis was not correlated to protection. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1399 / 1407
页数:9
相关论文
共 36 条
[1]   The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals [J].
Addo, MM ;
Altfeld, M ;
Rosenberg, ES ;
Eldridge, RL ;
Philips, MN ;
Habeeb, K ;
Khatri, A ;
Brander, C ;
Robbins, GK ;
Mazzara, GP ;
Goulder, PJR ;
Walker, BD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1781-1786
[2]   Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication [J].
Allen, TM ;
Mortara, L ;
Mothé, BR ;
Liebl, M ;
Jing, PC ;
Calore, B ;
Piekarczyk, M ;
Ruddersdorf, R ;
O'Connor, DH ;
Wang, X ;
Wang, CX ;
Allison, DB ;
Altman, JD ;
Sette, A ;
Desrosiers, RC ;
Sutter, G ;
Watkins, DI .
JOURNAL OF VIROLOGY, 2002, 76 (08) :4108-4112
[3]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[4]   The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4+ T cells and secrete gamma interferon after coapplication onto bare skin [J].
Beignon, AS ;
Briand, JP ;
Rappuoli, R ;
Muller, S ;
Partidos, CD .
INFECTION AND IMMUNITY, 2002, 70 (06) :3012-3019
[5]   Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals [J].
Belliard, G ;
Romieu, A ;
Zagury, JF ;
Dali, F ;
Chaloin, O ;
Le Grand, R ;
Loret, E ;
Briand, JP ;
Roques, B ;
Desgranges, C ;
Muller, S .
VACCINE, 2003, 21 (23) :3186-3199
[6]   Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [J].
Cafaro, A ;
Caputo, A ;
Fracasso, C ;
Maggiorella, MT ;
Goletti, D ;
Baroncelli, S ;
Pace, M ;
Sernicola, L ;
Koanga-Mogtomo, ML ;
Betti, M ;
Borsetti, A ;
Belli, R ;
Åkerblom, L ;
Corrias, F ;
Buttò, S ;
Heeney, J ;
Verani, P ;
Titti, F ;
Ensoli, B .
NATURE MEDICINE, 1999, 5 (06) :643-650
[7]   Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P) [J].
Cafaro, A ;
Titti, F ;
Fracasso, C ;
Maggiorella, MT ;
Baroncelli, S ;
Caputo, A ;
Goletti, D ;
Borsetti, A ;
Pace, M ;
Fanales-Belasio, E ;
Ridolfi, B ;
Negri, DRM ;
Sernicola, L ;
Belli, R ;
Corrias, F ;
Macchia, I ;
Leone, P ;
Michelini, Z ;
ten Haaft, P ;
Buttò, S ;
Verani, P ;
Ensoli, B .
VACCINE, 2001, 19 (20-22) :2862-2877
[8]   SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine [J].
Cafaro, A ;
Caputo, A ;
Maggiorella, MT ;
Baroncelli, S ;
Fracasso, C ;
Pace, M ;
Borsetti, A ;
Sernicola, L ;
Negri, DRM ;
Ten Haaft, P ;
Betti, M ;
Michelini, Z ;
Macchia, I ;
Fanales-Belasio, E ;
Belli, R ;
Corrias, F ;
Buttò, S ;
Verani, P ;
Titti, F ;
Ensoli, B .
JOURNAL OF MEDICAL PRIMATOLOGY, 2000, 29 (3-4) :193-208
[9]  
Demirhan I, 1999, J ACQ IMMUN DEF SYND, V22, P364
[10]   High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai [J].
Dunn, CS ;
Beyer, C ;
Kieny, MP ;
Gloeckler, L ;
Schmitt, D ;
Gut, JP ;
Kirn, A ;
Aubertin, AM .
VIROLOGY, 1996, 223 (02) :351-361